If there is a scientific analog of having one’s cake and eating it too, it would have to be iPS cells.
News & Commentaries
The stem cell community recorded something of a milestone this past month.
In the Oct. 20 issue of Nature, researchers at the Wellcome Trust Sanger Institute and Sangamo BioSciences, reported some dramatic results in the field of stem cell therapeutics. 
The fast-paced, vibrant world of stem cell science has more than its fair share of brilliant minds. Many probably have at one time or another considered striking out on their own to market some new invention from their lab.
Human development is the work of stem cells.
On April 19, Geron Corp. presented safety data on the first patient in its groundbreaking clinical trial of GRNOPC1.
On January 3, stem cell therapeutics company Advanced Cell Technology (ACT) announced it had received approval from the US Food and Drug Administration to kick off a Phase I/II clinical trial using the company's retinal epithelial cells (RPE).
You don’t need much scaffolding for a one-story home, but if you’re putting up a high-rise, you’ll require plenty of it to create the rising edifice.
California researchers are set to begin the first clinical trial of souped-up stem cells that seek and destroy brain cancer by delivering the means to make a potent chemotherapeutic.
While many stem cell scientists are basking in the afterglow of induced pluripotency, and working on ways to de-differentiate and re-differentiate cells, a few researchers are already thinking about a shortcut.